A unique Novo Nordisk legal challenge to the Medicare drug pricing program could have big implications for the pharma ...

When should six drugs count as one? That question is at the heart of an unusual challenge that the pharma company Novo Nordisk is pursuing against the federal government. And the answer could have ...

Shares of Novo Nordisk ended higher on Monday and extended gains in after-hours trading, while "Big Pharma" rival Eli Lilly ...

confirmed that it will not proceed with a Biden administration proposal to expand Medicare coverage for anti-obesity drugs ...

The Centers for Medicare & Medicaid Services said on Friday it did not move forward with a proposal put forth by the Biden ...

The FDA had rejected the companies’ initial application in 2023, requesting additional data after the pharma firms reported ...

Medicare Advantage updates while halting proposed anti-obesity drug coverage, impacting millions of potential beneficiaries.

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Trump officials reject Medicare coverage of anti-obesity drugsThe Trump administration says it will ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

A proposal by the Biden administration to cover weight-loss medicines for obesity under Medicare has been axed by the White ...

Novo Nordisk joined the many pharmaceutical companies pushing back on government-negotiated drug pricing in the United States.

The Trump administration will not permit Medicare to pay for obesity drugs directly ... The decision is a setback for drugmakers, especially Novo Nordisk and Eli Lilly, that had sought a green light.